- Conditions
- Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
- Interventions
- Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- San Diego, California • Orlando, Florida • Overland Park, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 4:07 AM EDT